nach oben

Erschienen in:

18.06.2021 | original article

Impact of COVID-19 pandemic on outpatient appointments of rheumatic patients in a non-outbreak area of China

verfasst von: Tianhua Xie, MD, Dong Wang, MD, Xia Wang, MD, Qingrui Yang, MD, Hongsheng Sun, MD, Ruihong Liu, MD, Ming Li, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 17-18/2021

Einloggen, um Zugang zu erhalten

Summary

Background

Coronavirus disease 2019 (COVID-19) infection has caused huge impacts on all of people’s lives and health systems. In response to the COVID-19 pandemic, China was the first country to impose lockdown. We aimed to study the influence of COVID-19 on the outpatient visits of rheumatic patients in a non-outbreak area of China.

Methods

We selected three provincial or ministerial hospitals in Jinan, and collected the outpatient appointments data in rheumatology and immunology departments during the Shandong Province first-level public health emergency response period from 25 January 2020 to 8 March 2020.

Results

In the early stage, the number of outpatient appointments in the rheumatology and immunology departments of the three provincial or ministerial hospitals were significantly reduced, and gradually restored in the late stage. It showed that in the face of major infectious diseases, strict quarantine measures with the cooperation of the public not only controls the epidemic in a short time, but also lifts the quarantine measures and opens general outpatient clinics in hospitals as soon as possible, thus minimizing the impact on other patients.

Interpretation

The impact on the western hospital was greater than that on the Chinese medicine hospital, and the impact on the back-up designated hospitals for COVID-19 was the greatest. Online appointment can reduce the risk of infection in outpatients, but not completely solve the follow-up problem of rheumatic patients. Telemedicine provides a new solution for both management of rheumatic patients and control of COVID-19.

Vorheriger Artikel The neutrophil to lymphocyte ratio is an independent predictor for severe COVID-19

Nächster Artikel COVID-19-associated myoclonus in a series of five critically ill patients

Zhu N, Zhang D, Wang W, et al. China novel Coronavirus investigating and research team. A novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.CrossRef

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV‑2. Nat Microbiol. 2020;5(4):536–44. https://doi.org/10.1038/s41564-020-0695-z.CrossRef

World Health Organization. Coronavirus disease (COVID-19).. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 28 June 2020.

Heinz FX, Stiasny K. Profiles of current COVID-19 vaccines. Wien Klin Wochenschr. 2021;16:1–13. https://doi.org/10.1007/s00508-021-01835-w. PMID: 33725201; PMCID: PMC7962631.CrossRef

Zhang J, Litvinova M, Liang Y, et al. Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. Science. 2020;368(6498):1481–6. https://doi.org/10.1126/science.abb8001.CrossRefPubMedPubMedCentral

Civil Protection Department, Government of Italy. Chronology of main steps and legal acts taken by the Italian Government for the containment of the COVID-19 epidemiological emergency.. http://www.protezionecivile.gov.it/documents/20182/1227694/Summary+of+measures+taken+against+the+spread+of+C-19/c16459ad-4e52-4e90-90f3-c6a2b30c17eb. Accessed 28 June 2020.

Motta Zanin G, Gentile E, Parisi A, Spasiano D. A preliminary evaluation of the public risk perception related to the COVID-19 health emergency in Italy. Int J Environ Res Public Health. 2020;17(9):3024. https://doi.org/10.3390/ijerph17093024.CrossRefPubMedCentral

Department of Economic and Social Affairs Population Dynamics, the United Nations. World population prospects 2019.. https://population.un.org/wpp/DataSources/. Accessed 28 June 2020.

Giesecke J. The invisible pandemic. Lancet. 2020;395(10238):e98. https://doi.org/10.1016/S0140-6736(20)31035-7.CrossRefPubMedPubMedCentral

10.

Viale G, Licata L, Sica L, et al. Personalized risk-benefit ratio adaptation of breast cancer care at the epicenter of COVID-19 outbreak. Oncologist. 2020;25(7):e1013–e20. https://doi.org/10.1634/theoncologist.2020-0316.CrossRefPubMedPubMedCentral

11.

Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020;395(10231):1225–8. https://doi.org/10.1016/S0140-6736(20)30627-9.CrossRefPubMedPubMedCentral

12.

Fagiuoli S, Lorini F, Remuzzi G. Covid-19 Bergamo hospital crisis unit. Adaptations and lessons in the province of Bergamo. N Engl J Med. 2020;382(21):e71. https://doi.org/10.1056/NEJMc2011599.CrossRefPubMed

13.

Cash R, Patel V. Has COVID-19 subverted global health? Lancet. 2020;395(10238):1687–8. https://doi.org/10.1016/S0140-6736(20)31089-8.CrossRefPubMedPubMedCentral

14.

Rosenbaum L. The untold toll—The pandemic’s effects on patients without Covid-19. N Engl J Med. 2020;382(24):2368–71. https://doi.org/10.1056/NEJMms2009984.CrossRefPubMed

15.

De Rosa S, Spaccarotella C, Basso C, et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. 2020;41(22):2083–8. https://doi.org/10.1093/eurheartj/ehaa409.CrossRefPubMed

16.

Caporali R, Favalli E. Managing patients with rheumatic conditions during the covid-19 pandemic. BMJ. 2020;369:m1633. https://doi.org/10.1136/bmj.m1633.CrossRefPubMed

17.

Michaud K, Wipfler K, Shaw Y, et al. Experiences of patients with rheumatic diseases in the United States during early days of the COVID-19 pandemic. ACR Open Rheumatol. 2020;2(6):335–43. https://doi.org/10.1002/acr2.11148.CrossRefPubMedPubMedCentral

18.

Yuwen Y, Shi NN, Wang LY, Xie YM, Han XJ, Lu AP. Development of clinical practice guidelines in 11 common diseases with Chinese medicine interventions in China. Chin J Integr Med. 2012;18(2):112–9. https://doi.org/10.1007/s11655-012-0997-y.CrossRefPubMed

19.

Liu Y, Tu S, Gao W, et al. Extracts of tripterygium wilfordii hook F in the treatment of rheumatoid arthritis: a systemic review and meta-analysis of randomised controlled trials. Evid Based Complement Alternat Med. 2013;2013:410793. https://doi.org/10.1155/2013/410793.CrossRefPubMedPubMedCentral

20.

Ho L, Lai J. Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders. Curr Drug Metab. 2004;5(2):181–92. https://doi.org/10.2174/1389200043489081.CrossRefPubMed

21.

Zhang P, Li J, Han Y, Yu XW, Qin L. Traditional Chinese medicine in the treatment of rheumatoid arthritis: a general review. Rheumatol Int. 2010;30(6):713–8. https://doi.org/10.1007/s00296-010-1370-0.CrossRefPubMed

22.

Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-new Coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci. 2020;16(10):1708–17. https://doi.org/10.7150/ijbs.45538.CrossRefPubMedPubMedCentral

23.

Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann Rheum Dis. 2016;75(1):136–41. https://doi.org/10.1136/annrheumdis-2014-206334.CrossRefPubMed

24.

Kato E, Sawada T, Tahara K, et al. The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study. Int J Rheum Dis. 2017;20(7):839–45. https://doi.org/10.1111/1756-185X.12998.CrossRefPubMed

25.

Zhang X, Yu P, Yan J, Spil ITAM. Using diffusion of innovation theory to understand the factors impacting patient acceptance and use of consumer e‑health innovations: a case study in a primary care clinic. BMC Health Serv Res. 2015;15:71. https://doi.org/10.1186/s12913-015-0726-2.CrossRefPubMedPubMedCentral

26.

Smolen J, Breedveld F, Burmester G, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15. https://doi.org/10.1136/annrheumdis-2015-207524.CrossRefPubMed

27.

Schulze-Koops H, Specker C, Iking-Konert C, Holle J, Moosig F, Krueger K. Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic. Ann Rheum Dis. 2020;79(6):840–2. https://doi.org/10.1136/annrheumdis-2020-217628.CrossRefPubMed

28.

Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 2. Arthritis Rheumatol. 2020; https://doi.org/10.1002/art.41437.CrossRefPubMed

29.

Heymann D. Data sharing and outbreaks: best practice exemplified. Lancet. 2020;395(10223):469–70. https://doi.org/10.1016/S0140-6736(20)30184-7.CrossRefPubMedPubMedCentral

30.

Zhang H. Early lessons from the frontline of the 2019-nCoV outbreak. Lancet. 2020;395(10225):687. https://doi.org/10.1016/S0140-6736(20)30356-1.CrossRefPubMedPubMedCentral

31.

Habibi MRM, Mohammadabadi F, Tabesh H, Vakili-Arki H, Abu-Hanna A, Eslami S. Effect of an online appointment scheduling system on evaluation metrics of outpatient scheduling system: a before-after multicenterstudy. J Med Syst. 2019;43(8):281. https://doi.org/10.1007/s10916-019-1383-5.CrossRefPubMed

32.

Webster P. Virtual health care in the era of COVID-19. Lancet. 2020;395(10231):1180–1. https://doi.org/10.1016/S0140-6736(20)30818-7.CrossRefPubMedPubMedCentral

33.

Bakshi SS, Kalidoss VK. Patient concern inventory: an effective tool for easing telemedicine during the COVID-19 pandemic. Wien Klin Wochenschr. 2021;14:1–2. https://doi.org/10.1007/s00508-021-01860-9.CrossRef

34.

Gong K, Xu Z, Cai Z, Chen Y, Wang Z. Internet hospitals help prevent and control the epidemic of COVID-19 in China: multicenter user profiling study. J Med Internet Res. 2020;22(4):e18908. https://doi.org/10.2196/18908.CrossRefPubMedPubMedCentral

Titel: Impact of COVID-19 pandemic on outpatient appointments of rheumatic patients in a non-outbreak area of China
verfasst von: Tianhua Xie, MD
Dong Wang, MD
Xia Wang, MD
Qingrui Yang, MD
Hongsheng Sun, MD
Ruihong Liu, MD
Ming Li, MD
Publikationsdatum: 18.06.2021
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 17-18/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-021-01891-2

Springer Medizin Österreich

Summary

Background

Methods

Results

Interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 17-18/2021

MUW researcher of the month

Alterations of the male and female reproductive systems induced by COVID-19

Patient concern inventory: an effective tool for easing telemedicine during the COVID-19 pandemic

Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients

The neutrophil to lymphocyte ratio is an independent predictor for severe COVID-19

MUW researcher of the month